<HTML>
<HEAD>
<TITLE>LabOne, Inc. Form 8-K dated March 2, 2004</TITLE>
</HEAD>
<BODY>

<FONT SIZE=5><STRONG><P ALIGN="CENTER">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</P>
</FONT></STRONG><FONT SIZE=4><P ALIGN="CENTER">Washington, D.C. 20549</P>
</FONT><FONT SIZE=5><STRONG><P ALIGN="CENTER">FORM 8-K</P>
</FONT></STRONG><P ALIGN="CENTER">CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</P>
<P ALIGN="CENTER">Date of Report: <U>March 2, 2004</P>
</U><P ALIGN="CENTER">Commission file number: 0-16946</P>
<B><U><FONT FACE="Times,Times New Roman" SIZE=5><P ALIGN="CENTER">LabOne, Inc.</P>
</B></U></FONT><P ALIGN="CENTER">10101 Renner Blvd.</P>
<P ALIGN="CENTER">Lenexa, Kansas 66219</P>
<P ALIGN="CENTER">(913) 888-1770</P>
<FONT FACE="Times,Times New Roman"><P ALIGN="CENTER">Incorporated in Missouri</P>
<P ALIGN="CENTER">I.R.S. Employer Identification Number: 43-1039532</P>
</FONT><FONT FACE="Times,Times New Roman" SIZE=2><P>&nbsp;</P>
</FONT><P><HR ALIGN="RIGHT"></P>


<FONT FACE="Times,Times New Roman"><P>Item 9.&nbsp;&nbsp;Regulation FD Disclosure</P>
</FONT><P ALIGN="CENTER"><B>LabOne Signs Agreement to Provide Testing for
Anthem Blue Cross and Blue Shield
</B></P>

<P>LabOne, Inc. (Nasdaq: LABS), announced today that it has completed the purchase of the assets of the drug testing division, Northwest Toxicology, from NWT Inc., Salt Lake City.  The purchase price is $10.0 million subject to adjustment based on net working capital at closing, plus an earn-out for up to seven years based on the performance of the continuing laboratory operations in Salt Lake City less related financing. Prior to closing, Northwest Toxicology announced it would suspend hair testing for drugs of abuse on March 31, 2004, due to recent FDA guidance and anticipated regulatory changes. The acquisition will result in additional urine and oral fluid testing volumes directed to LabOne, and further the Company's capabilities to include drugs of abuse testing in blood, expanded specimen validity testing, medical professional and other esoteric drug testing. </P>

<P>Although LabOne expects to transition most of Northwest Toxicology's traditional urine and oral fluid testing to its Lenexa facility during 2004, the Northwest Toxicology laboratory in Salt Lake City will be maintained as a SAMHSA-certified laboratory. The acquisition is expected to add approximately $11 million in annual revenues, and to be accretive to earnings.</P>



<P>&nbsp;</P>
<P>&nbsp;</P>
</DIR>

<P><HR></P>
<P>&nbsp;&nbsp;</P>
<I><FONT SIZE=5><P ALIGN="CENTER">Signature</I></FONT><FONT FACE="Times,Times New Roman"> </P>
<P ALIGN="CENTER">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P ALIGN="CENTER">&nbsp;</FONT><FONT SIZE=5>LabOne, Inc.</P>
</FONT>
<CENTER>
<TABLE cellSpacing=0 cellPadding=10 width=524 border=0>
  <TR>
    <TD vAlign=top width="40%">
      <P>Date:&nbsp;&nbsp;March 2, 2004</P></TD>
    <TD vAlign=center width="60%">
      <P>By <U>/s/ <I>John W. McCarty</I></U><BR>John W. McCarty
      <BR>Executive V.P. and Chief Financial Officer
  </P></TD></TR>
</TABLE></CENTER>


</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "nwt8k.htm", "secsgml_size_bytes": 3283}]
{"company-data": {"conformed-name": "LABONE INC/", "cik": "0000830158", "assigned-sic": "8071", "irs-number": "431039532", "state-of-incorporation": "MO", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-92137", "film-number": "04641164"}, "business-address": {"street1": "10101 RENNER BLVD", "street2": "P. O. BOX 7568", "city": "LENEXA", "state": "KS", "zip": "66219", "phone": "9138881770"}, "mail-address": {"street1": "10101 RENNER BLVD", "street2": "X", "city": "LENEXA", "state": "KS", "zip": "66219"}, "former-company": [{"former-conformed-name": "LAB HOLDINGS INC", "date-changed": "19980406"}, {"former-conformed-name": "SEAFIELD CAPITAL CORP", "date-changed": "19920703"}, {"former-conformed-name": "SEAFIELD CAPTIAL CORP", "date-changed": "19910520"}]}
LabOne, Inc. Form 8-K dated March 2, 2004
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report:
March 2, 2004
Commission file number: 0-16946
LabOne, Inc.
10101 Renner Blvd.
Lenexa, Kansas 66219
(913) 888-1770
Incorporated in Missouri
I.R.S. Employer Identification Number: 43-1039532
Item 9.  Regulation FD Disclosure
LabOne Signs Agreement to Provide Testing for
Anthem Blue Cross and Blue Shield
LabOne, Inc. (Nasdaq: LABS), announced today that it has completed the purchase of the assets of the drug testing division, Northwest Toxicology, from NWT Inc., Salt Lake City.  The purchase price is $10.0 million subject to adjustment based on net working capital at closing, plus an earn-out for up to seven years based on the performance of the continuing laboratory operations in Salt Lake City less related financing. Prior to closing, Northwest Toxicology announced it would suspend hair testing for drugs of abuse on March 31, 2004, due to recent FDA guidance and anticipated regulatory changes. The acquisition will result in additional urine and oral fluid testing volumes directed to LabOne, and further the Company's capabilities to include drugs of abuse testing in blood, expanded specimen validity testing, medical professional and other esoteric drug testing.
Although LabOne expects to transition most of Northwest Toxicology's traditional urine and oral fluid testing to its Lenexa facility during 2004, the Northwest Toxicology laboratory in Salt Lake City will be maintained as a SAMHSA-certified laboratory. The acquisition is expected to add approximately $11 million in annual revenues, and to be accretive to earnings.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
LabOne, Inc.
Date:  March 2, 2004
By
/s/
John W. McCarty
John W. McCarty
Executive V.P. and Chief Financial Officer